eli lilly retatrutide phase 3 trial Lilly's triple agonist delivers up to 71.2 lbs of weight loss Eli Lilly just announced striking

Disadvantages include no additional support for common GLP-1 side effects

However, not all patients respond effectively to GLP-1R monoagonists, and higher doses aimed at increasing efficacy result in adverse gastrointestinal effects

Some patients may find injections uncomfortable or experience pain at the injection site, leading to decreased adherence to treatment

Weight maintenance is individualized: some patients stop, some cycle back on, and others stay on a lower maintenance dose

My doctors said my weight didnt really justify the use and seemed very unsure how to navigate all this, said Claire K., who ultimately secured Zepbound via a local nurse practitioner